Replies to post #398267 on Amarin Corp Plc (AMRN)

[Lrich]

"A good company" is not Amarin

They have proven time and time again that they are a terrible company due to terrible leadership. Incremental steps in refreshing the C-suite and the board have led us nowhere, but people are still delusional that "this time it's different" with a small change in leadership.

This isn't to say Vascepa is worthless, but considering how the key facets of making Amarin a good company have failed to materialize, despite these "refreshes" it is impossible for one to believe that adding a couple people hand picked by the people who suck will help. Celebrating the most basic of successes while ignoring glaring failures like massively overspending in Germany then retroactively claiming they knew they wouldn't get reimbursement right now is insane.

Also, how does 26 million shares give Denner the board? He'd need 180-210+ million shares to be guaranteed the board (67% of the outstanding, depending on exactly which share count is considered the full amount when it comes to tallying votes).

[north40000]

AMRN share price is + 72.73% since January 3, 2023. Some other food for thought re MITIGATE from iwfal on the Biotech Value board:

"The problem is almost certainly that, like other viral diseases, the mortality risk is substantially elevated for months after recovery. Eg, flu increases MI risk for several months after an infection. And COVID is much worse in that regard. US Military, Insurance Companies and UK NHS have all, separately, noted this large effect in the young, and the excess mortality started big climb in 2020 (ie, prior to vaccine).

This is a good summary of post recovery heart risks:

https://heart.bmj.com/content/heartjnl/early/2022/09/21/heartjnl-2022-321492.full.pdf

Probably the most interesting thing is a number of celebrities dying from unexpected/odd events within a few months of bad COVID infection."